Iterum Therapeutics to Present Data at IDWeek 2022 : vimarsa

Analysis of data from Phase 3 studies in uUTI and cUTI to assess the relevance of a positive urine culture in patients with no clinical symptoms after being treated for a UTINew data on the... | October 17, 2022

Related Keywords

Ireland , Dublin , Washington , United States , Chicago , Illinois , Judy Matthews , Sailaja Puttagunta , Steven Aronin , Idweek Interactive Program , Infectious Disease Society Of America Idweek , Waltere Washington Convention Center , Nasdaq , Infectious Disease Society , Convention Center , Interactive Program , Mobile App , Asymptomatic Bacteriuria , Primary Efficacy Analyses , Novel Antimicrobials , Urinary Tract , Murine Efficacy Studies , Sulopenem Against Bacillus , Iterum Therapeutics , Qualified Infectious Disease Product , Fast Track , Iterum Therapeutics Plc Stock Exchange , News , Information , Press Release , Analysis , F , Data , Rom , Hase , , Studies , N , Uti , End , O , Ssess , The , Relevance , Positive , Urine , Culture , Patients , Ith , Linical , Symptoms , After , Being , Reated , Or , Tinew , N Itrm Ie000ttoobx0 ,